Azienda Unita Locale Socio Sanitaria N 8 Berica

At Azienda Unita Locale Socio Sanitaria N 8 Berica in Vicenza, the Dermatology and Venereology Department is running studies focused on skin and connective tissue diseases, especially atopic dermatitis, plaque psoriasis, prurigo nodularis, and other chronic inflammatory skin conditions. These trials are mainly designed to assess new treatments, long-term safety, and sustained symptom control.

• Research in atopic dermatitis aims to improve disease control and evaluate the durability of newer therapies.
• Studies in psoriasis and prurigo nodularis are exploring better options for long-term relief and tolerability.
• The site also contributes to broader work on inflammatory skin disease by testing whether emerging therapies can offer more effective and convenient care.

This dermatology-focused portfolio reflects a strong interest in improving treatment options for people living with persistent, quality-of-life-impacting skin disorders.

A major part of the research activity at this hospital involves hemic and lymphatic diseases, with trials in acute leukemias, chronic myeloid leukemia, mantle cell lymphoma, myelofibrosis, and multiple myeloma. The studies are aimed at improving remission rates, reducing relapse, and finding better treatment strategies for both newly diagnosed and difficult-to-treat blood cancers.

• Trials in acute leukemia are testing new approaches to achieve deeper and more durable responses.
• Research in lymphoma and myelofibrosis is evaluating whether newer therapies can improve survival and disease control.
• The site also studies chronic myeloid leukemia and related disorders to refine treatment sequencing and long-term outcomes.

This area shows a broad commitment to advancing care for complex blood cancers and other serious hematologic conditions.

The site is active in neoplasms affecting the digestive system, including colorectal cancer, gastric cancer, gastroesophageal junction adenocarcinoma, cholangiocarcinoma, pancreatic ductal adenocarcinoma, and hepatocellular carcinoma. These trials often compare new treatment combinations with standard care to improve survival and disease control.

• Studies in colorectal cancer are focused on post-surgery risk reduction, treatment sequencing, and biomarker-guided care.
• Trials in gastric and gastroesophageal cancer are assessing new targeted and immune-based treatment options.
• Research in liver, bile duct, and pancreatic cancers aims to improve first-line treatment effectiveness.

This oncology portfolio reflects a strong focus on improving outcomes in some of the most challenging digestive system cancers.

Clinical trials at the site also cover female urogenital diseases and pregnancy complications, with a strong emphasis on ovarian cancer, endometrial cancer, cervical cancer, and vulvar cancer. The research is centered on testing new therapies, improving maintenance strategies, and refining treatment for recurrent or metastatic disease.

• Studies in ovarian and endometrial cancer are evaluating ways to extend disease control after initial treatment.
• Research in cervical cancer is examining new options for patients whose disease has returned or progressed.
• The work also includes advanced gynecologic cancers to better tailor treatment for difficult-to-manage cases.

This field highlights ongoing efforts to improve both survival and quality of life in women’s cancer care.

Another important research stream involves immune system diseases and hemic disorders, including immune thrombocytopenia, hemophilia A, hemophilia B, thrombotic thrombocytopenic purpura, paroxysmal nocturnal hemoglobinuria, and venous thromboembolism. These trials are designed to improve prevention, control bleeding or clotting complications, and evaluate safer long-term management approaches.

• Research in immune thrombocytopenia and thrombotic thrombocytopenic purpura is focused on better disease control and reducing complications.
• Studies in hemophilia aim to support improved clotting factor replacement and bleeding prevention.
• Trials in venous thromboembolism are evaluating strategies to prevent recurrence while balancing bleeding risk.

At this Vicenza site, the work in hemostasis and immune-mediated blood disease research is especially relevant for patients needing long-term, carefully balanced treatment.

The trial portfolio also includes cardiovascular diseases, kidney disease, and other supportive-care areas such as nausea, vomiting, and treatment-related side effects. These studies are aimed at improving prevention, protecting organ function, and making cancer care safer and more tolerable.

• Research in chronic kidney disease is evaluating ways to slow progression and protect heart and kidney health.
• Studies in cardiac care include efforts to reduce low-output complications after surgery.
• Supportive-care trials are looking at better control of treatment-related symptoms and adverse reactions.

This broader research area shows the site’s interest in improving both disease-specific outcomes and the overall safety of treatment.